Company Overview - BioAge Labs is a clinical-stage biopharmaceutical company focused on developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging [3] - The company's lead product candidate, azelaprag, is an orally available small molecule agonist of APJ, which has shown potential in promoting metabolism and preventing muscle atrophy during bed rest in a Phase 1b clinical trial [3] - BioAge initiated a Phase 2 trial of azelaprag in combination with tirzepatide for treating obesity in older adults in mid-2024 [3] Product Development - Azelaprag has potential as an oral regimen to enhance weight loss and improve body composition in patients undergoing obesity therapy with incretin drugs [3] - The company is also developing orally available small molecule brain penetrant NLRP3 inhibitors aimed at treating diseases driven by neuroinflammation [3] - BioAge's preclinical programs leverage insights from its discovery platform based on human longevity data to address key pathways in metabolic aging [3] Upcoming Events - BioAge Labs will present at the Goldman Sachs Second Annual "Year-Ahead" Catalyst Clinic on December 19, 2024, from 11 AM to 12 PM EST [1] - A live webcast of the presentation will be available, with replays accessible in the investor section of the company's website for 30 days following the event [2]
BioAge Labs to Present at Goldman Sachs “Year-Ahead” Catalyst Clinic